Clinical studies have also provided evidence that avelumab, an anti-PD-L1 antibody, shows moderate efficacy and is well tolerated in advanced HCC patients previously treated with sorafenib (Lee et al., 2021). Here, CD274 is linked to hepatocellular carcinoma.